BeiGene Ltd/ US07725L1026 /
2024-03-27 9:00:00 PM | Chg. +1.2700 | Volume | Bid2:03:50 PM | Ask2:03:50 PM | High | Low |
---|---|---|---|---|---|---|
155.0800USD | +0.83% | 76,134 Turnover: 6.3 mill. |
154.6100Bid Size: 100 | 159.1900Ask Size: 100 | 155.9150 | 153.0500 |
GlobeNewswire
11:00 AM
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
GlobeNewswire
03-05
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the ...
GlobeNewswire
02-27
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
GlobeNewswire
02-27
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights ...
GlobeNewswire
02-08
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire
01-08
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the ...
GlobeNewswire
2023-11-07
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire
2023-11-07
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disea...
GlobeNewswire
2023-11-02
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
GlobeNewswire
2023-10-20
NFL HEAD COACH PLEDGES TO PAY FORWARD SUPPORT HE RECEIVED WHEN FACING CANCER DIAGNOSIS